Elevated salivary alpha-amylase levels at awakening in patients with depression
| Autor: | S.E.E.C. Bauduin, E.J. Giltay, N.J.A. van der Wee, S.J.A. van der Werff, M.S. van Noorden, M. de Leeuw, A.M. van Hemert |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Evening Hydrocortisone Endocrinology Diabetes and Metabolism Salivary cortisol Anxiety behavioral disciplines and activities Cohort Studies 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine mental disorders Humans Medicine Saliva Biological Psychiatry Depression (differential diagnoses) Depressive Disorder Major Depression Endocrine and Autonomic Systems business.industry Area under the curve Middle Aged Salivary alpha amylase medicine.disease Anxiety Disorders 030227 psychiatry Affect Psychiatry and Mental health Mood Salivary alpha-Amylases Case-Control Studies Cohort Major depressive disorder Biomarker (medicine) Female alpha-Amylases medicine.symptom business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Psychoneuroendocrinology, 97, 69-77 |
| ISSN: | 0306-4530 |
| DOI: | 10.1016/j.psyneuen.2018.07.001 |
| Popis: | Background Specific Major Depressive Disorder (MDD) biomarkers could help improve our understanding of MDD pathophysiology and aid in the refinement of current MDD criteria. While salivary cortisol (SC) can differentiate between healthy controls and patients with psychiatric disorders, salivary alpha amylase (sAA), may be a putative candidate biomarker for MDD specifically. Methods In a naturalistic cohort of consecutive out-patients and healthy controls, sAA and SC were determined in 833 participants (97 MDD patients, 142 patients with other mood, anxiety, and/or somatoform (MAS-) disorders, and 594 healthy controls). Samples were collected at 7 different time points (at awakening, after 30, 45, and 60 min, at 10:00 p.m., at 11:00 p.m., and at awakening on day 2). Results The mean age of the sample was 43.8 years (SD = 12.9; 63.9% female). Concerning sAA, MDD patients had higher sAA levels upon awakening on two consecutive days (p = 0.04, p = 0.01 respectively), as well as a higher area under the curve with respect to the increase (AUCi; p = 0.04) in comparison to both controls and the other MAS-disorders group. Regarding SC, mean levels of evening SC were elevated in MDD patients (p = 0.049) in comparison to both controls and the other MAS-disorders group. SC values on day 2 after ingestion of dexamethasone were elevated in both MDD patients and the other MAS-disorders group (p = 0.04, p = 0.047 respectively). Conclusions sAA at awakening and not cortisol differentiates MDD from other psychiatric disorders in outpatients. This suggests that sAA may be a valuable candidate biomarker specifically for MDD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect